Cited by 222Nanoparticle-Based Drug DeliverySepsis Diagnosis and TreatmentRNA Interference and Gene Delivery

Bioresponsive Nanoparticles Targeted to Infectious Microenvironments for Sepsis Management

Open access
Zhang, Can Yang, Gao, Jin, Wang, Zhenjia·2018·Advanced Materials

Abstract

Sepsis is a life‐threatening disease resulted from a dysregulated host immune response to bacterial infections, continuing to cause high morbidity and mortality worldwide. Despite discoveries of many potential therapeutic targets, effective treatments of sepsis are lacking. Here, a strategy is reported to target infectious microenvironments (IMEs) via bioresponsive nanoparticles that simultaneously eliminate bacteria and alleviate the host inflammation response, thus managing sepsis in mice. The nanoparticle is made of copolymers sensitive to pH and bacterial enzymes to self‐assemble into a micelle loaded with both an antibiotic (ciprofloxacin) and an anti‐inflammatory agent ((2‐[(aminocarbonyl)amino]‐5‐(4‐fluorophenyl)‐3‐thiophenecarboxamide). In addition, the nanoparticle is conjugated with intercellular adhesion molecule‐1 antibodies to target IMEs. Nanoparticle targeting to IMEs and local cues as triggers to deliver therapeutics in on‐demand manners is demonstrated using an acute lung bacterial infection mouse model. In the sepsis mouse model induced by peritonitis at a lethal dose of bacterial invasion, it is shown that concurrently targeting pathogens and excessive inflammation pathways is valuable to manage the sepsis. The study illustrates not only the development of a new delivery system but also the mechanism‐based therapy of nanomedicine for infectious diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adma.201803618

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a mouse model of pulmonary P. aeruginosa infection, treatment with targeted nanoparticles improved survival over the free-drug control by nearly 50 percentage points.

    “In a mouse model of pulmonary P. aeruginosa infection, treatment with targeted nanoparticles improved survival over the free-drug control by nearly 50 percentage points.”

    From Nanotechnology approaches for global infectious diseases (2021) · cites this paper as [62]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 5

  1. [17]Radovic-Moreno AF, Lu TK, Puscasu VA, Yoon CJ, Langer R, Farokhzad OC, ACS Nano 2012, 6, 4279. 22471841 PMC3779925
  2. [19]Zeiler H-J, Grohe K, Ciprofloxacin 1986, 14, 14.
  3. [31]Ritger PL, Peppas NA, Controlled Release J 1987, 5, 37.
  4. [32]a) Li Y, Li H, Wei M, Lu J, Jin L, Chem. Eng. J 2009, 151, 359; b) Costa P, Lobo J. M. Sousa, Eur. J. Pharm. Sci 2001, 13, 123. 11297896
  5. [36]Madhi SA, Klugman KP, The Vaccine Trialist Group, Nat. Med 2004, 10, 811. 15247911 PMC7095883

Cited by

Sorted by citations

Authors
Zhang, C. Y., Gao, J., & Wang, Z.
Affiliations
Washington State University Spokane (US)
Corresponding author
Wang, Zhenjia
Venue
Advanced Materials
Publisher
Wiley
Published
2018-09-11
Volume
30
Issue
43
Pages
e1803618-e1803618
ISSN
  • 0935-9648 (ISSN-L)
  • 1521-4095
OpenAlex
W2890443562
Cited by
222
References
59
Citations by year
2026: 10 · 2025: 25 · 2024: 32 · 2023: 40 · 2022: 32 · 2021: 34 · 2020: 25 · 2019: 21 · 2018: 2
FWCI
6.63
Type
journal article
Language
en
Open access
Locations
  • Advanced Materials (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of General Medical Sciences (RO1GM116823)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Epidemiology › Sepsis Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
sepsis, pH-responsive polymers, enzyme-responsive polymers, micelles, ciprofloxacin, anti-inflammatory agents, targeted drug delivery, bacterial infection, peritonitis, pulmonary infection, inflammation, nanomedicine
MeSH terms
Proof of Concept Study, Amides, Animals, Anti-Inflammatory Agents, Non-Steroidal, Anti-Bacterial Agents, Bacterial Proteins, Ciprofloxacin, Disease Models, Animal, Humans, Hydrogen-Ion Concentration, Lung Diseases, Micelles, Peritonitis, Polymers, Thiophenes, Drug Design, Drug Delivery Systems, Sepsis, Mice, Nanoparticles, Human Umbilical Vein Endothelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review